Description / human IGF-BP6 protein
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
More Information
| Size | 20 µg |
|---|---|
| Source | Insect cells |
| Biological Activity | Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 – 0.4 μg/ml. |
| Purity Confirmation | > 95% by SDS-PAGE & HPLC analyses |
| Length [aa] | 213 |
| Molecular Weight | 22.6 kDa |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Protein Sequence | RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG |
| Synonyms | Igfbp6; IBP6 |
| Uniprot ID | P24592 |
| Protein RefSeq | NP_002169.1 |
| mRNA RefSeq | NM_002178 |